Deucravacitinib (TYK2) in PsA from POETYK trials Improved ACR20 at wk16 (NNT ~5), less benefit for ACR70 (NNT ~20) Steady improvements during open label extension (all pts received drug) Would expect approval for PsA soon... where will this fit in your approach? @RheumNow https://t.co/325h2hf0AE

• https://x.com/EBRheum/status/1983566474951393426/photo/1
• https://x.com/EBRheum/status/1983566474951393426/photo/1

Thank you @drdavidliew & @DrLauraCoates ❤️ for highlighting our work. Super-responders (some were IS-Free) do exist with rituximab in #SLE Abstr#1525 @RheumNow https://t.co/S4mMAYInfT

• https://twitter.com/drdavidliew/status/1983555936657854811

Autologous CAR-Treg in RA, without any lymphodepletion preRx Early data from ph1, single dose Good initial response, stopped RA Rx, but some rebound Clearly work ongoing but excitement re: - CAR-Treg - RA as target dx - no lymphodepletion @minnakohlermd #ACR25 LB23 @RheumNow https://t.co/azmlFNU02R

• https://x.com/drdavidliew/status/1983540424632615108/photo/1
• https://x.com/drdavidliew/status/1983540424632615108/photo/1
• https://x.com/drdavidliew/status/1983540424632615108/photo/1
• https://x.com/drdavidliew/status/1983540424632615108/photo/1

REGULATE RA SBT-77-701 Engineered Treg cell in Refractory RA population 6patients Safety and tolerability: No DLT, CRS or ICANS Efficacy Reduction >50% in TJC and SJC 67% reduction of DAS-CRP >=2 stained up to wk 24 Impressive in pts for whom it works, yet a couple seem to https://t.co/lQAQABPhg0

• https://x.com/AurelieRheumo/status/1983539634459074639/photo/1
• https://x.com/AurelieRheumo/status/1983539634459074639/photo/1
• https://x.com/AurelieRheumo/status/1983539634459074639/photo/1

#ACR25 Abstr#LB23 Phase 1 trial in 5 refractory #RA of SBT777101, a novel autologous CAR-Treg (without the need for lymphodepletion) showed promising efficacy and safety signal. No DLT, CRS or ICANS. Looking forward to larger data and in other RMDs @RheumNow https://t.co/YyGMSHjA3z

• https://x.com/Yuz6Yusof/status/1983537965545685387/photo/1
• https://x.com/Yuz6Yusof/status/1983537965545685387/photo/1

Turns out you can directly degrade NETs. Holy smokes NETs critical in pathology of SLE & other dx They’ve found you can target it Enzymatic degrader fused to albumin Proof-of-concept: degraded a patient’s SLE manifestations in hours Definitely one to watch #ACR25 LB22 @RheumNow https://t.co/HVEt8wFYmI

• https://x.com/drdavidliew/status/1983535986475974994/photo/1
• https://x.com/drdavidliew/status/1983535986475974994/photo/1
• https://x.com/drdavidliew/status/1983535986475974994/photo/1

Microbiome signature for prediction of response to MTX in RA: Yay or Nay? Microbiome analysis 60pts, 23 MTX NR BL enrichment in specific species in MTX NR Looking at the graphs though, seems to be driven by a few pts Prediction model doesn't seem to perform greatly Sens 88% https://t.co/1yrSXdE6DG

• https://x.com/AurelieRheumo/status/1983534365045854650/photo/1

Regulate-RA study, first-in-human Phase 1 study data show citrullinated protein (CitP)-targeted CAR-Tregs (SBT777101) are safe and show early efficacy in refractory RA. 67% had ≥50% joint count reduction by Week 4. A novel, non-cytotoxic approach to immune modulation for https://t.co/g153w3XVEK

• https://x.com/synovialjoints/status/1983534285941313978/photo/1

The next VEXAS, but also maybe we can treat it? IDH1/2 Another clonal hematopoesis known to cause heme malignancy, but also some inflamm sequelae (autoinflamm-like e.g. PMR/GCA) & you can directly inhibit it Wow. We will hear more #ACR25 LB21 @RheumNow https://t.co/WL2ai5zb8Q https://t.co/Yi31xkhLO9

• IDH1/2 Somatic Hotspot Mutations as Independent Drivers of Autoinflammation - A…
• https://x.com/drdavidliew/status/1983533459428741520/photo/1

Ph2B RCT of Rosnilimab Tcell depleter (PD-1high Tph/Tfh, Teff) Wk 12 Primary Endpoint met Mean change DAS28-CRP at Wk 12 SC rosnilimab 100mg Q4W -2.06 400mg Q4W -2.12 600mg Q2W -2.06 PBO -1.69 >90% peripheral and synovial depletion pathogenic T cells 28 Wk Safety profile: https://t.co/XyVhJamFdp

• https://x.com/AurelieRheumo/status/1983529880982519845/photo/1
• https://x.com/AurelieRheumo/status/1983529880982519845/photo/1

POETYK PsA-1 (one of paired deucravacitinib in PsA ph3 registration studies) Oral med Good outcomes Safety very good but the bar is very high nowadays in PsA Questions splicing through depth of response Definitely will find a place in therapy, but where? #ACR25 LB19 @RheumNow https://t.co/iqmHQrMTYN

• https://x.com/drdavidliew/status/1983528271653564853/photo/1
• https://x.com/drdavidliew/status/1983528271653564853/photo/1

POETYK PsA 1 and 2 Deucravacitinib TYK2 inhibitor Ph3 RCT 52 wks data Deucra 336pts PBO 334pts then crossover wk 16 to 52 Pooled analysis wk 16 ACR 20 54% vs. 31% Enthesitis reduction LEI 52% vs. 45% Dactylics resolution 58% vs. 44% POETYK-PsA 1 Wk 52 ACR 20 63% ACR50 44% PASI https://t.co/LYJbU8fYwI

• https://x.com/AurelieRheumo/status/1983526852019855385/photo/1
• https://x.com/AurelieRheumo/status/1983526852019855385/photo/1
• https://x.com/AurelieRheumo/status/1983526852019855385/photo/1

In POETYK PsA-1, deucravacitinib showed sustained efficacy through Week 52 in PsA, improving joint, skin, PROs, and radiographic progression. Safety remained favorable with no new signals. TYK2 inhibition continues to show promise. Abstract#LB20 @RheumNow #ACR25 https://t.co/sGkk062HqJ

• https://x.com/synovialjoints/status/1983526734398881939/photo/1

Questions #ACR25 LB20 to Paul Emery on rosnilimab: Fleischmann: could be induction therapy? (Not intent, but could be) Choy: Depth of changes with translational data Tanaka: Safety given peresolimab ph2b here (diff epitope, membrane proximity, targeted depletion PD-1hi) @RheumNow

Mease et al. 52 week results deucravacitinib in PsA. Approx ACR20 60%, ACR50 40%, ACR70 25%. Sustained radiographic benefit. No new safety signals @RheumNow #ACR25 Abstr#LB20 https://t.co/vKqjb08mI8

• https://x.com/RichardPAConway/status/1983525475965132800/photo/1